"Omalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.
| Descriptor ID |
D000069444
|
| MeSH Number(s) |
D12.776.124.486.485.114.071.500 D12.776.124.486.485.114.224.060.844 D12.776.124.790.651.114.071.500 D12.776.124.790.651.114.224.060.844 D12.776.377.715.548.114.071.500 D12.776.377.715.548.114.224.200.844
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Omalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Anti-Idiotypic [D12.776.124.486.485.114.071]
- Omalizumab [D12.776.124.486.485.114.071.500]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Omalizumab [D12.776.124.486.485.114.224.060.844]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Anti-Idiotypic [D12.776.124.790.651.114.071]
- Omalizumab [D12.776.124.790.651.114.071.500]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Omalizumab [D12.776.124.790.651.114.224.060.844]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Anti-Idiotypic [D12.776.377.715.548.114.071]
- Omalizumab [D12.776.377.715.548.114.071.500]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Omalizumab [D12.776.377.715.548.114.224.200.844]
Below are MeSH descriptors whose meaning is more specific than "Omalizumab".
This graph shows the total number of publications written about "Omalizumab" by people in this website by year, and whether "Omalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 0 | 3 |
| 2020 | 0 | 4 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 5 | 3 | 8 |
| 2025 | 0 | 1 | 1 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Omalizumab" by people in Profiles.
-
Preventing Food Anaphylaxis. Immunol Allergy Clin North Am. 2026 May; 46(2):257-273.
-
The use of omalizumab in food allergy. Allergy. 2024 10; 79(10):2888-2889.
-
Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021 01; 100:106228.
-
Oral Immunotherapy for Peanut Allergy. Annu Rev Med. 2016; 67:375-85.
-
Lichen planus associated with omalizumab administration in an adult with allergic asthma. Ann Allergy Asthma Immunol. 2009 Apr; 102(4):349-51.